ArticleScientific reports2017
Immune responses against Helicobacter pylori-specific antigens differentiate relapsing remitting from secondary progressive multiple sclerosis.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Association ofFrontiers in medicine · 2025Pooled it
- Evaluation of Seropositivity Developed Against Specific Antigens ofNoro psikiyatri arsivi · 2026Article
- Review
- Investigating the link between Helicobacter pylori infection and psoriatic disease: an immunological study.Immunologic research · 2024Article
- Latent microbial infections leading to myelin and axonal damage in multiple sclerosis: A narrative review.Current journal of neurology · 2024Article
- Helicobacter pylori infection and Parkinson's Disease: etiology, pathogenesis and levodopa bioavailability.Immunity & ageing : I & A · 2024Review
- The Probable Infectious Origin of Multiple Sclerosis.NeuroSci · 2023Review
- Therapies for Parkinson's disease and the gut microbiome: evidence for bidirectional connection.Frontiers in aging neuroscience · 2023Review
- Review
- Update to the Treatment of Parkinson's Disease Based on the Gut-Brain Axis Mechanism.Frontiers in neuroscience · 2022Review
- Review
- Association of helicobacter pylori with multiple sclerosis: Protective or risk factor?Current journal of neurology · 2020Article
- Antigen-specific humoral responses against Helicobacter pylori in patients with systemic sclerosis.Immunologic research · 2020Article
- Immune-mediated genesis of multiple sclerosis.Journal of translational autoimmunity · 2020Review
- Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options.Auto- immunity highlights · 2019Review
- Altered Gut Microbiome and Intestinal Pathology in Parkinson's Disease.Journal of movement disorders · 2019Article
- CpG Island Methylation Patterns in Relapsing-Remitting Multiple Sclerosis.Journal of molecular neuroscience : MN · 2018Article
- Bacteria-Host Interactions in Multiple Sclerosis.Frontiers in microbiology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To assess whether Helicobacter pylori (Hp) antibody (ab) reactivity against individual Hp antigens is pathogenetically relevant to multiple sclerosis (MS), we systematically investigated prevalence and clinical significance of abs against 14 immunodominant and subdominant Hp antigens by ELISA and immunoblotting in 139 consecutive MS patients with relapsing-remitting (RRMS, n = 102) or secondary progressive (SPMS, n = 37). Sera from 39 patients with Parkinson's disease (PD), 21 with Alzheimer's disease (ALZ) and 68 healthy controls (HCs), were also tested. Anti-flagellin (18.3%) and anti-p41 (25.0%) abs in MS were less frequent than in HCs (39.4%, 48.5%, respectively). Abs against 5 of the 14 antigens were less frequent in RRMS than HCs, including p41, p54-flagellin, p29-UreA, p67-FSH, and p120-CagA. Anti-VacA abs were more frequent in SPMS than in HCs (42.1 vs 12.1%, p = 0.019). Anti-p54, anti-p29-UreA and anti-p26 correlated with extended disability status scale (EDSS) (p = 0.017, p = 0.005, p = 0.002, respectively). Anti-p26 and anti-p17 correlated with the number of relapses (p = 0.037 and p = 0.047, respectively). This is the first comprehensive analysis of ab reactivities against most Hp antigens in MS patients. Ab responses differ between MS and HCs and between RRMS and SPMS, being more prevalent in SPMS than RRMS, thus suggesting an association between anti-Hp and the former type of MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.